Replies to post #540 on Eagle Pharmaceuticals, inc. (EGRX)

[bio_fan]

Mizuho increases PT to 78.

We expect Teva to convert 95% of the market to Bendeka before 2019 but then decline share to 70% in 2020, and all the way down to 58% in 2026," Koffler wrote. Eagle no longer has "take-back" rights to Bendeka, but its royalty increases to 25% from 20% in January.